Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Webcasts|May 21, 2020
Ensuring Integrity of Drug Formulation from Development to QC
Author(s)Thermo Fisher Scientific
Learn how to reduce the number of steps and resources needed to assure chemical and structural integrity throughout drug development process. See where efficiencies can be gained in analytical methods development and transfer to QC and manufacturing while staying compliant with cGxP. Thursday, May 21, 2020 at 10am EDT | 9am CDT | 3pm BST | 4pm CEST On demand available after final airing May 21, 2021 Register free
Register free:
Event Overview:
After a small molecule has been identified as a viable drug candidate, substantial testing is required to assure that chemical and structural integrity are preserved throughout the drug development process to maintain its functionality. To keep a balance between quality and manufacturability, time-consuming and labor-intensive testing and analysis are required to demonstrate that chemical integrity is intact. Among the techniques used to study changes in chemical integrity are infrared and Raman spectroscopy.
This webcast will discuss where efficiencies can be made in data collection, regulatory compliance, instrument qualification, method validation, and data integrity all along the development pipeline up to final quality control (QC) testing. Learn how to quickly identify changes in polymorphic structure, monitor API to excipient distribution, and troubleshoot out-of-specification (OOS) product lots, while preserving data integrity needed for audits.
Key Learning Objectives:
- Where along the drug development path can FTIR, NIR and Raman techniques be used and what knowledge is gained
- How to minimize the number of laborious steps in analytical method validation, verification, and transfer to QC and manufacturing
- What to look for in a hardware-software platform to not only assure drug formulation integrity but also data integrity
Speakers: Michael Bradley, Ph.D, Senior Manager, Global Training, Thermo Fisher Scientific
Katherine Paulsen, Product Manager – Routine Spectroscopy, Thermo Fisher Scientific
Mike Garry, Sr. Product Manager – NIR Spectroscopy, Thermo Fisher Scientific
Time and Date: Thursday, May 21, 2020 at 10am EDT | 9am CDT | 3pm BST | 4pm CEST
On demand available after final airing May 21, 2021
Sponsor: Thermo Fisher Scientific
Register free:
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5